BCL2 and small cell lung carcinoma: It has been reported that Venetoclax could interrupt the interaction between BCL2 and the BIM complex, thereby destabilizing the BIM protein and activating PARP cleavage in a BCL2 expressing the small-cell lung cancer cell line [56].